Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Iscador*P

Phase 2Small molecule

HHackensack Meridian Health

Iscador*P is one of 17 small molecule programs targeting Sarcoma. It is currently in Phase 2.

1

Indications

1

Total Trials

1

Active Trials

16

Competitors

Pipeline

Status by Indication[3][1]

Indication

SarcomaRecruiting

SarcomaPhase 2

Recruiting

Competition

Competitive Landscape

18 competitors in Sarcoma

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Keytruda

Tecentriq

IC-Green

PProvepharm SAS

Amtagvi

IIovance Biotherapeutics, Inc.

Talimogene Laherparepvec

Biological

NNational Environment Agency, Singapore

NKTR-214

Bristol-Myers Squibb

Rapamune

PPrism Pharmaceuticals

NEULASTA

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Sarcoma

NCT05726383

Clinical

Trials by Indication[1]

Sarcoma1 trial

MISTOSUS: Iscador® P (Mistletoe) Immunotherapy To Improve Event Free Survival In Patients With Relapsed Resectable Osteosarcoma

Recruiting·HHackensack Meridian Health·Phase 2·NCT05726383·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Iscador*P. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Iscador*P compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Iscador*P. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hackensack Meridian Health company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHackensack Meridian Health

Related News